Figure 3From: Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I studyPlots illustrating total plasma β-amyloid levels of individual patients by time and dose level. (A) β-amyloid (18–35) Aβ18–35. (B) Aβ28–42. GSK: GSK933776. Patients = 6 for each dose group.Back to article page